AMENDMENTS TO THE CLAIMS

- 1. (Canceled).
- 2. (Canceled).
- 3. (Canceled).
- 4. (Canceled).
- 5. (Canceled).
- 6. (Canceled.)
- 7. (Canceled).
- 8. (Canceled).
- 9. (Canceled).
- 10. (Canceled).
- 11. (Canceled).
- 12. (Canceled).
- 13. (Canceled).
- 14. (Canceled).
- 15. (Canceled).
- 16. (Canceled).

- 17. (Previously presented) An isolated estrogen receptor- β comprising the sequence depicted in Figure 4, SEQ ID. NO:2.
 - 18. (Canceled).
- 19. (Previously presented) A method for identifying hER β -interactive compounds, said method comprising:
- (a) contacting the polypeptide of claim 17 with a labeled ligand in the presence of test compounds, to form test reactions, and in the absence of test compounds, to form control reactions;
- (b) incubating said test and control reactions under appropriate conditions to achieve equilibrium binding of said labeled ligand to hER β ;
- (c) determining the level of binding of said labeled ligand to hER β in said test and control cultures; and
- (d) identifying as a hER β -interactive compound any compound that reduces the binding of said labeled ligand to hER β .
- 20. (Original) A method as defined in claim 19, wherein said ligand is $17-\beta$ estradiol.
- 21. (Original) A method as defined in claim 19, wherein said hER β -interactive compound is an agonist.
- 22. (Original) A method as defined in claim 19, wherein said hER β -interactive compound is an antagonist.
 - 23. (Canceled).
 - 24. (Canceled).

25.	(Canceled).
26.	(Canceled).
27.	(Canceled).
	(Previously presented) The polypeptide of claim 17, wherein the polypeptide is a label capable of providing a detectable signal.
29. radioisotope.	(Previously presented) The polypeptide of claim 28, wherein the signal is a
30. fluorescent con	(Previously presented) The polypeptide of claim 28, wherein the signal is a npound.
31.	(Canceled).
32.	(Canceled).
33.	(Canceled).
34. produced in int	(Previously presented) The polypeptide of claim 17, wherein the polypeptide is act cells.
	(Previously presented)The polypeptide of claim 17, wherein the polypeptide is ll-free translation systems.
36.	(Canceled).
37.	(Canceled).
38. chemically syn	(Previously presented) The polypeptide of claim 17, wherein the polypeptide is thesized.

- 39. (Previously presented) The polypeptide of claim 17, wherein the polypeptide is produced in a recombinant system.
 - 40. (Canceled).
 - 41. (Canceled).

In view of the above, the Examiner is respectfully requested to pass this application to

Dated: 1/22/02/

issue.

Respectfully submitted,

Kristin E. Behrendt

Registration No.: 45,599

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant